Trial · NCT00023322
Pegylated Interferon to Treat Chronic Hepatitis D
NCT00023322, Phase 2, Completed, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); results first posted 2013-07-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pegylated Interferon to Treat Chronic Hepatitis D. Trials, record NCT00023322. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00023322
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pegylated Interferon to Treat Chronic Hepatitis D
- NCT number
- NCT00023322
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 13 participants, actual
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Conditions
- Hepatitis D
- Interventions
- Peginterferon Alpha-2a
- First posted
- 2001-09-03
- Last updated
- 2013-07-10
- Results first posted
- 2013-07-10
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Histological Response at 3 Years | 3 years | Histological response is defined as at least 3 point improvement in inflammatory score or 1 point improvement in fibrosis score of the HAI at each liver biopsy. |
| Secondary | Histological Response at 5 Years | 5 years | Histological response is defined as at least 3 point improvement in inflammatory score or 1 point improvement in fibrosis score of the HAI at each liver biopsy. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Histological Response at 3 Years | 3 years | Intention to treat | participants | NUMBER |
| SECONDARY | Histological Response at 5 Years | 5 years | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Histological Response at 3 Years | Peginterferon Alpha-2a | 6 | participants | ||
| Histological Response at 5 Years | Peginterferon Alpha-2a | 6 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Peginterferon Alpha-2a | 13 | |
| Overall Study | COMPLETED | Peginterferon Alpha-2a | 12 | |
| Overall Study | NOT COMPLETED | Peginterferon Alpha-2a | 1 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | soft tissue infection | Skin and subcutaneous tissue disorders | Peginterferon Alpha-2a | 1 | 12 | 1 |
| other | autoinflammatory syndrome | Infections and infestations | Peginterferon Alpha-2a | 1 | 12 | 1 |
| other | subarachnoid hemorrhage | Blood and lymphatic system disorders | Peginterferon Alpha-2a | 1 | 12 | 1 |
| serious | Death | Hepatobiliary disorders | Peginterferon Alpha-2a | 1 | 12 | 1 |
| serious | Death | Hepatobiliary disorders | Peginterferon Alpha-2a | 1 | 12 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Peginterferon Alpha-2a | ||
| Total, other adverse events | Peginterferon Alpha-2a | 3 | 12 |
| Total, serious adverse events | Peginterferon Alpha-2a | 1 | 12 |
Source ClinicalTrials.gov
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00023322
GET https://conductscience.org/api/trials/v1/NCT00023322/registered